Suppr超能文献

共病酒精和阿片类药物使用的药物治疗管理。

Pharmacotherapeutic management of co-morbid alcohol and opioid use.

机构信息

Department of Psychology, Arizona State University , Tempe, AZ, USA.

出版信息

Expert Opin Pharmacother. 2020 May;21(7):823-839. doi: 10.1080/14656566.2020.1732349. Epub 2020 Feb 27.

Abstract

Opioid use disorder (OUD) and alcohol use disorder (AUD) are two highly prevalent substance-related disorders worldwide. Co-use of the substances is also quite prevalent, yet there are no pharmacological treatment approaches specifically designed to treat co-morbid OUD and AUD. Here, the authors critically summarize OUD, AUD and opioid/alcohol co-use and their current pharmacotherapies for treatment. They also review the mechanisms of action of opioids and alcohol within the brain reward circuitry and discuss potential combined mechanisms of action and resulting neuroadaptations. Pharmacotherapies that aim to treat AUD or OUD that may be beneficial in the treatment of co-use are also highlighted. Preclinical models assessing alcohol and opioid co-use remain sparse. Lasting neuroadaptations in brain reward circuits caused by co-use of alcohol and opioids remains largely understudied. In order to fully understand the neurobiological underpinnings of alcohol and opioid co-use and develop efficacious pharmacotherapies, the preclinical field must expand its current experimental paradigms of 'single drug' use to encompass polysubstance use. Such studies will provide insights on the neural alterations induced by opioid and alcohol co-use, and may help develop novel pharmacotherapies for individuals with co-occurring alcohol and opioid use disorders.

摘要

阿片类使用障碍(OUD)和酒精使用障碍(AUD)是全球两种高度流行的物质相关障碍。这些物质的共同使用也相当普遍,但目前还没有专门设计用于治疗共病性 OUD 和 AUD 的药理学治疗方法。在这里,作者批判性地总结了 OUD、AUD 和阿片类药物/酒精共同使用及其当前的治疗药理学。他们还回顾了阿片类药物和酒精在大脑奖励回路中的作用机制,并讨论了潜在的联合作用机制和由此产生的神经适应。还强调了旨在治疗 AUD 或 OUD 的药物治疗方法可能对共同使用的治疗有益。评估酒精和阿片类药物共同使用的临床前模型仍然很少。酒精和阿片类药物共同使用引起的大脑奖励回路的持久神经适应在很大程度上仍未得到充分研究。为了充分了解酒精和阿片类药物共同使用的神经生物学基础并开发有效的药物治疗方法,临床前领域必须将其当前的“单一药物”使用实验范式扩展到包含多物质使用。这些研究将提供关于阿片类药物和酒精共同使用引起的神经改变的见解,并可能有助于为同时患有酒精和阿片类药物使用障碍的个体开发新的药物治疗方法。

相似文献

1
Pharmacotherapeutic management of co-morbid alcohol and opioid use.
Expert Opin Pharmacother. 2020 May;21(7):823-839. doi: 10.1080/14656566.2020.1732349. Epub 2020 Feb 27.
2
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
JAMA Netw Open. 2021 Feb 1;4(2):e210061. doi: 10.1001/jamanetworkopen.2021.0061.
3
Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder.
J Subst Use Addict Treat. 2024 Sep;164:209339. doi: 10.1016/j.josat.2024.209339. Epub 2024 Mar 19.
4
Rational development of addiction pharmacotherapies: successes, failures, and prospects.
Cold Spring Harb Perspect Med. 2012 Jun;2(6):a012880. doi: 10.1101/cshperspect.a012880.
5
Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.
Alcohol Clin Exp Res. 2018 Mar;42(3):478-488. doi: 10.1111/acer.13594. Epub 2018 Feb 6.
6
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Drugs. 2020 Oct;80(15):1509-1524. doi: 10.1007/s40265-020-01373-1.
7
Pharmacotherapies for treating opioid use disorder.
CNS Spectr. 2013 Dec;18(6):289-95. doi: 10.1017/S1092852913000229. Epub 2013 Apr 8.
8
Pharmacotherapy for Substance Use Disorders.
Med Clin North Am. 2016 Jul;100(4):891-910. doi: 10.1016/j.mcna.2016.03.011. Epub 2016 Apr 20.
9
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
Ann N Y Acad Sci. 2014 Oct;1327(1):112-30. doi: 10.1111/nyas.12538. Epub 2014 Sep 18.
10
Nonmedical prescription sedative/tranquilizer use in alcohol and opioid use disorders.
Addict Behav. 2019 Jan;88:48-55. doi: 10.1016/j.addbeh.2018.08.010. Epub 2018 Aug 14.

引用本文的文献

2
BK channels and alcohol tolerance: Insights from studies on , nematodes, rodents and cell lines: A systematic review.
Med Int (Lond). 2025 Apr 2;5(4):33. doi: 10.3892/mi.2025.232. eCollection 2025 Jul-Aug.
3
Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70008. doi: 10.1002/wnan.70008.
4
The Role of Endogenous Beta-Endorphin and Enkephalins in the Crosstalk Between Ethanol and Morphine.
Pharmaceuticals (Basel). 2025 Jan 16;18(1):107. doi: 10.3390/ph18010107.
7
Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder.
J Subst Use Addict Treat. 2024 Sep;164:209339. doi: 10.1016/j.josat.2024.209339. Epub 2024 Mar 19.
8
Concurrent opioid and alcohol withdrawal management.
Ment Health Clin. 2023 Dec 1;13(6):268-275. doi: 10.9740/mhc.2023.12.268. eCollection 2023 Dec.
9
Role of aldosterone and mineralocorticoid receptor (MR) in addiction: A scoping review.
Neurosci Biobehav Rev. 2023 Nov;154:105427. doi: 10.1016/j.neubiorev.2023.105427. Epub 2023 Oct 17.
10
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
Expert Opin Pharmacother. 2022 Nov;23(16):1819-1830. doi: 10.1080/14656566.2022.2140039. Epub 2022 Nov 14.

本文引用的文献

1
Pain severity and prescription opioid misuse among individuals with chronic pain: The moderating role of alcohol use severity.
Drug Alcohol Depend. 2019 Nov 1;204:107456. doi: 10.1016/j.drugalcdep.2019.02.036. Epub 2019 Aug 22.
3
Binge Drinking and Prescription Opioid Misuse in the U.S., 2012-2014.
Am J Prev Med. 2019 Aug;57(2):197-208. doi: 10.1016/j.amepre.2019.02.025. Epub 2019 Jun 11.
5
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Contemp Clin Trials. 2019 Jun;81:102-109. doi: 10.1016/j.cct.2019.04.006. Epub 2019 Apr 12.
6
Co-occurring substance use and mental disorders among adults with opioid use disorder.
Drug Alcohol Depend. 2019 Apr 1;197:78-82. doi: 10.1016/j.drugalcdep.2018.12.030. Epub 2019 Feb 14.
7
Characterizing chronic pain and alcohol use trajectory among treatment-seeking alcoholics.
Alcohol. 2019 Mar;75:47-54. doi: 10.1016/j.alcohol.2018.05.009. Epub 2018 May 25.
8
Stress and Alcohol Priming of Brain Toll-Like Receptor Signaling in Alcohol Use Disorder.
Alcohol Alcohol. 2018 Nov 1;53(6):639-641. doi: 10.1093/alcalc/agy061.
9
Ethanol acts on KCNK13 potassium channels in the ventral tegmental area to increase firing rate and modulate binge-like drinking.
Neuropharmacology. 2019 Jan;144:29-36. doi: 10.1016/j.neuropharm.2018.10.008. Epub 2018 Oct 14.
10
Acamprosate's ethanol intake-reducing effect is associated with its ability to increase dopamine.
Pharmacol Biochem Behav. 2018 Dec;175:101-107. doi: 10.1016/j.pbb.2018.09.009. Epub 2018 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验